The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

View Congress Resources by Therapeutic Area
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Showing 6 of 44 results
Sort by date: Descending
Encores: Not included
Bipolar Disorder
Schizophrenia
ASCP 2025 POSTER
Lipid and Glycemic Profile of Olanzapine and Samidorphan: A Patient Subgroup Analysis of a 4-Year Open-Label Study
AUTHOR(S)

Jacob S. Ballon, MD, MPH,1 Christina Arevalo, MS,2 Alexandra Lovett, MD,2 Christoph U. Correll, MD3-6

View poster
Listen to Audio Abstract
0:00 0:00
Bipolar Disorder
Schizophrenia
Sleep-wake disorders
ISPOR 2025 POSTER
The Economic Burden of Narcolepsy in the United States: Matched Analysis of National Health and Wellness Survey Data
AUTHOR(S)

Michael J. Doane1, Kiran P. Maski2, M. Janelle Cambron-Mellott3, Shakiba Eslamimehr3, Adam Jauregui3, Wilbur P. Williams, III1

View poster
Listen to Audio Abstract
0:00 0:00
Sleep-wake disorders
Schizophrenia
AMCP 2025 POSTER
Treatment Patterns and Healthcare Resource Utilization of Patients Early in Schizophrenia Illness Initiating Aripiprazole Lauroxil Versus Oral Aripiprazole: A Retrospective Claims-Based Study
AUTHOR(S)

John M. Kane,1 Regina Grebla,2 Michael J. Doane,2 Andrea B. Barthel,3 Chenxue Liang,3 Zhengfan Wang,3 Elizabeth S. Nagelhout,3 Lauren N. Strand2

View poster
Listen to Audio Abstract
0:00 0:00
Schizophrenia
Bipolar Disorder
Schizophrenia
SIRS 2025 POSTER
Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan: A Patient Subgroup Analysis of a 4-Year Open-Label Study
AUTHOR(S)

Jacob S. Ballon, MD, MPH,1 Christina Arevalo, MS,2 Martin Dunbar, PhD,2 Alexandra Lovett, MD,2 David McDonnell, MD,3 Christoph U. Correll, MD4-7

View poster
Listen to Audio Abstract
0:00 0:00
Bipolar Disorder
Schizophrenia
Bipolar Disorder
USPC 2024 POSTER
Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Bipolar I Disorder
AUTHOR(S)

Rakesh Jain, MD, MPH,1 Hemangi R. Panchmatia, MSc,2 Alejandro G. Hughes, MPH,3 Michael J. Doane, PhD,2 Hara E. Oyedeji, CRNP, MS,4 Andrew J. Cutler, MD5,6

View poster
Bipolar Disorder
Schizophrenia
USPC 2024 POSTER
Healthcare Resource Utilization 12 Months Following Initiation of Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia
AUTHOR(S)

Andrew J. Cutler, MD,1,2 Hemangi R. Panchmatia, MSc,3 Alejandro G. Hughes, MPH,4 Michael J. Doane, PhD,3 Hara E. Oyedeji, CRNP, MS,5 Rakesh Jain, MD, MPH6

View poster
Schizophrenia